United States securities and exchange commission logo October 7, 2022 Laura Shawver, Ph.D. Chief Executive Officer Silverback Therapeutics, Inc. 500 Fairview Ave. N, Suite 600 Seattle, Washington 98109 Re: Silverback Therapeutics, Inc. Preliminary Proxy Statement on Schedule 14A Filed August 11, 2022 File No. 001-39756 Dear Laura Shawver: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Kenneth J. Rollins, Esq.